---
url: https://www.servicesaustralia.gov.au/severe-chronic-plaque-psoriasis-toxicity-and-severity-descriptors
title: Severe chronic plaque psoriasis toxicity and severity descriptors - Health professionals - Services AustraliaServices AustraliaServices Australia
scrapedAt: 2026-02-20T21:44:03.017Z
source: servicesaustralia.gov.au
---
# Severe chronic plaque psoriasis toxicity and severity descriptors

Toxicity and severity descriptors for treatments required to be trialled before accessing PBS-subsidised biological medicines to treat severe chronic plaque psoriasis in adults.

## on this page

-   [Acitretin](#a1)
-   [Cyclosporin](#a2)
-   [Methotrexate](#a3)
-   [Phototherapy toxicity](#a4)
-   [Apremilast](#a5)
-   [Deucravacitinib](#a6)

## Acitretin

**At least 0.4mg/kg/day**

Adverse event

Brief description of minimum grade of toxicity

National Institutes of Health common toxicity criteria grade

Bilirubin

\> 1.5 x ULN

2 (or higher)

Transaminases

ALT and/or AST > 2.5 x ULN or ALT and/or AST > 1.5 x ULN on 3 occasions over a 3-month period

2 (or higher)

Serum alkaline phosphatase

2.5 x ULN

2 (or higher)

Use contraindicated in those with pre-existing significant renal disease

Creatinine > 1.5 ULN

2 (or higher)

Retinoic acid syndrome

Symptoms of a degree to indicate steroid use

2 (or higher)

Pseudotumour cerebri

Headache, nausea and vomiting associated with raised intracranial pressure

 

Nausea

Oral intake significantly decreased

2 (or higher)

Skin peeling

Development of fissures on the palms and soles which cause sufficient discomfort and pain to prevent normal day-to-day duties, and which haven't responded to regular and liberal applications of a moisturising agent

 

Skin burning

Sufficient to disturb activities of daily living and to disturb the normal sleep pattern

 

## Cyclosporin

**At least 2 mg/kg/day**

Adverse event

Brief description of minimum grade of toxicity

National Institutes of Health  
common toxicity criteria grade

**Blood/bone marrow**

Anaemia

Haemoglobin < 80 g/L

3 (or higher)

Leukopenia

Total WCC < 3 x 109/L

2 (or higher)

Thrombocytopenia

Platelets < 50 x 109/L

3 (or higher)

Neutropenia

Total neutrophils < 1.0 x 109/L

3 (or higher)

**Cardiovascular**

Hypertension

Recurrent/persistent rise of > 20 mmHg diastolic BP or rise to > 150/90 on 2 occasions if BP previously normal

2 (or higher)

Fluid retention

Symptomatic, limiting function, unresponsive to therapy or requiring drug discontinuation

3 (or higher)

**Dermatology/skin**

Rash/desquamation

Scattered macular or papular eruption or erythema with pruritis or other associated symptoms covering < 50% of body surface or localised desquamation or other lesions covering < 50% of body

2 (or higher)

**Gastrointestinal**

Diarrhoea

Increase of 4-6 stools/day over pre-treatment

2 (or higher)

Nausea

Oral intake significantly decreased

2 (or higher)

Pancreatitis

Abdominal pain with pancreatic enzyme elevation

3 (or higher)

Vomiting

2 or more episodes/24 hours over pre-treatment

2 (or higher)

Weight gain/loss

20% or more weight gain or loss

3 (or higher)

**Hepatic**

Bilirubin

\> 1.5 x ULN

2 (or higher)

Transaminases

ALT and/or AST > 2.5 x ULN or ALT and/or AST > 1.5 x ULN on three occasions over a 3-month period

2 (or higher)

g Serum alkaline phosphatase

2.5 x ULN

2 (or higher)

**Musculoskeletal**

Muscle weakness

Symptomatic and interfering with function

2 (or higher)

**Neurology/senses**

Ataxia (incoordination)

Mild symptoms interfering with function but not interfering with activities of daily living

2 (or higher)

Decreased level of consciousness

Somnolence or sedation interfering with function but not interfering with activities of daily living

2 (or higher)

Headaches (severe)

Severe pain: pain or analgesics that severely interfere with activities of daily living

3 (or higher)

Hearing

Tinnitus or hearing loss not requiring hearing aid or treatment

2 (or higher)

Mood alteration

Moderate mood alteration interfering with function but not interfering with activities of daily living

2 (or higher)

Neuropathy -sensory

Objective sensory loss or paraesthesia interfering with function but not interfering with activities of daily living

2 (or higher)

Seizure(s)

Seizures in which consciousness is altered

3 (or higher)

Vision

Symptomatic and interfering with function but not interfering with activities of daily living

2 (or higher)

**Renal**

Haematuria

Macroscopic (or dipstick +++) confirmed on two separate occasions

2 (or higher)

Proteinuria

\> 1.0g/24 hours, elevated urine protein/creatinine ratios, (dipstick protein ++ or greater), confirmed on 2 separate occasions

2 (or higher)

Renal impairment

Creatinine > 1.5 ULN or creatinine clearance < 30mL/min

2 (or higher)

**Other**

Allergic reaction

Urticaria, drug fever > 38°C and/or bronchospasm

2 (or higher)

Fatigue/malaise

Severe, loss of ability to perform some activities

3 (or higher)

Fever (in the absence of neutropenia)

Body temp > 39°C (oral or tympanic)

2 (or higher)

Hyperkalaemia

Potassium > 6 mmol/L

3 (or higher)

Infection

Severe, systemic infection, requiring IV antimicrobial treatment or hospitalisation

3 (or higher)

Secondary malignancy

Secondary malignancy present

4

## Methotrexate

**At least 10 mg weekly**

Adverse event

Brief description of minimum grade of toxicity

National Institutes of Health  
common toxicity criteria grade

**Blood/bone marrow**

Anaemia

Haemoglobin < 80 g/L

3 (or higher)

Leukopenia

Total WCC < 3 x 109/L

2 (or higher)

Thrombocytopenia

Platelets < 50 x 109/L

3 (or higher)

Neutropenia

Total neutrophils < 1.0 x 109/L

3 (or higher)

**Cardiovascular**

Pericardial effusion/pericarditis

Pericarditis (pericardial rub, ECG changes or chest pain)

2 (or higher)

Thrombosis/embolism

Requiring anticoagulant therapy

3 (or higher)

**Dermatology/skin**

Alopecia

Pronounced hair loss

2 (or higher)

Rash/desquamation

Scattered macular or papular eruption or erythema with pruritis or other associated symptoms covering < 50% of body surface or localised desquamation or other lesions covering < 50% of body

2 (or higher)

**Gastrointestinal**

Diarrhoea

Increase of 4-6 stools/day over pre-treatment

2 (or higher)

Nausea

Oral intake significantly decreased, and symptoms do not improve with at least 2 of the following measures:

1.  reduction of the methotrexate dose
2.  folinic acid/folic acid supplementation
3.  switching from oral to intramuscular dosing
4.  dividing the methotrexate dose over 12 hours.

A minimum of 3 doses of methotrexate should have been trialled

2 (or higher)

Pancreatitis

Abdominal pain with pancreatic enzyme elevation

3 (or higher)

Stomatitis

Painful erythema, oedema or ulcers but able to eat or swallow

2 (or higher)

Vomiting

2 or more episodes/24 hours over pre-treatment

2 (or higher)

**Hepatic**

Bilirubin

\> 1.5 x ULN

2 (or higher)

Transaminases

ALT and/or AST > 2.5 x ULN or ALT and/or AST > 1.5 x ULN on three occasions over a 3 month period

2 (or higher)

g Serum alkaline phosphatase

2.5 x ULN

2 (or higher)

**Musculoskeletal**

Osteonecrosis

Symptomatic and interfering with function

2 (or higher) (avascular necrosis)

Osteoporosis

Symptomatic and requiring treatment

3 (or higher)

**Neurology/senses**

Decreased level of consciousness

Somnolence or sedation interfering with function but not interfering with activities of daily living

2 (or higher)

Headaches (severe)

Severe pain: pain or analgesics that severely interfere with activities of daily living

3 (or higher)

Hearing

Tinnitus or hearing loss not requiring hearing aid or treatment

2 (or higher)

Mood alteration

Moderate mood alteration interfering with function but not interfering with activities of daily living

2 (or higher)

Seizure(s)

Seizures in which consciousness is altered

3 (or higher)

Vision

Symptomatic and interfering with function but not interfering with activities of daily living

2 (or higher)

**Pulmonary**

Cough (severe)

Severe cough or coughing spasm, poor control or unresponsive to treatment. Evidence of reversal on cessation of treatment

3 (or higher)

Pneumonitis/pulmonary infiltrates

Radiographic changes, Respiratory Function Test abnormalities and requiring steroids or diuretics

2 (or higher)

Pulmonary fibrosis

Respiratory Function Test abnormalities and requiring steroids or diuretics

2 (or higher)

Pulmonary symptoms -new or worsening (probable drug-induced pneumonitis)

Development of syndrome consistent with drug-induced pneumonitis (e.g. cough, dyspnoea, fever,

 

**Renal**

Haematuria

Macroscopic (or dipstick +++) confirmed on 2 separate occasions

2 (or higher)

Renal impairment

Creatinine > 1.5 ULN or creatinine clearance < 30mL/min

2 (or higher)

**Other**

Allergic reaction

Urticaria, drug fever > 38°C and/or bronchospasm

2 (or higher)

Fatigue/malaise

Severe, loss of ability to perform some activities

3 (or higher)

Fever (in the absence of neutropenia)

Body temp > 39°C (oral or tympanic)

2 (or higher)

Infection

Severe, systemic infection, requiring IV antimicrobial treatment or hospitalisation

3 (or higher)

Secondary malignancy

Secondary malignancy present

4

## Phototherapy toxicity

**Required minimum dose of 3 treatments per week**

Adverse event

Brief description of minimum grade of toxicity

National Institutes of Health  
common toxicity criteria grade

Severe photosensitivity reaction

Erythema with desquamation

3 (or higher)

Pruritis

Intense or widespread and interfering with activities of daily living (ADLs)

3 (or higher)

Development of melanoma

 

 

Development of non melanoma skin cancer

 

 

Development of more than 10 actinic keratoses

 

 

Nausea (PUVA)

Oral intake significantly decreased. A minimum of 3 doses should be trialled

2 (or higher)

More than 200 combined phototherapy treatments

 

 

## Apremilast

**Required minimum dose of 30 mg twice daily**

Adverse event

Brief description of minimum grade of toxicity

National Institutes of Health  
common toxicity criteria grade

**Gastrointestinal**

Diarrhoea

Increase of 4-6 stools per day over baseline; moderate increase in ostomy output compared to baseline

2 (or higher)

Nausea

Oral intake decreased without significant weight loss, dehydration or malnutrition

2 (or higher)

Vomiting

3-5 episodes (separated by 5 minutes) in 24 hrs

2 (or higher)

Abdominal pain

Moderate pain; limiting instrumental ADL

2 (or higher)

GORD

Moderate symptoms; medical intervention indicated

2 (or higher)

**General Disorders/administrative site**

Fatigue

Fatigue not relieved by rest; limiting instrumental ADL

2 (or higher)

Weight decrease

10 - <20% from baseline; nutritional support indicated

2 (or higher)

**Immune System**

Hypersensitivity

Intervention or interruption to treatment indicated; responds promptly to symptomatic treatment (e.g., antihistamines, NSAIDS, narcotics); prophylactic medications indicated for <=24 hrs

2 (or higher)

**Infections/infestations**

Bronchitis

Moderate symptoms; oral intervention indicated (e.g., antibiotic, antifungal, antiviral)

2 (or higher)

Upper respiratory tract infection

Moderate symptoms; oral intervention indicated (e.g., antibiotic, antifungal, antiviral)

2 (or higher)

Decreased appetite

Oral intake altered without significant weight loss or malnutrition; oral nutritional supplements indicated

2 (or higher)

**Musculoskeletal/connective tissue**

Back pain

Moderate back pain; prescription analgesics indicated; limiting instrumental ADL

2 (or higher)

**Nervous system**

Migraine

Moderate pain; limiting instrumental ADL

2 (or higher)

Tension headache

Moderate pain; limiting instrumental ADL

2 (or higher)

**Psychiatric**

Insomnia

Moderate difficulty falling asleep, staying asleep or waking up early

2 (or higher)

**Respiratory/thoracic/mediastinal**

Cough

Moderate symptoms, medical intervention indicated; limiting instrumental ADL

2 (or higher)

**Skin/subcutaneous tissue**

Rash

Localized; local intervention indicated (e.g., topical antibiotic, antifungal, or antiviral)

2 (or higher)

## Deucravacitinib

**6 mg once daily**

**Adverse event**

**Brief description of minimum grade of toxicity**

**National Institutes of Health**  
**common toxicity criteria grade**

**Infections**

Upper respiratory tract infections

Moderate symptoms; oral intervention indicated (e.g., antibiotic, antifungal, antiviral)

2 (or higher)

Herpes simplex infections

Moderate symptoms; oral intervention indicated (e.g. antiviral)

2 (or higher)

**Cardiovascular**

Hypertension

Recurrent/persistent rise of > 20 mmHg diastolic BP or rise to > 150/90 on 2 occasions if BP previously normal

2 (or higher)

**Dermatology/skin**

Acneiform rash/folliculitis

Papules and/or pustules covering 10-30% BSA, which may or may not be associated with symptoms of pruritus or tenderness

2 (or higher)

**Gastrointestinal**

Diarrhoea

Increase of 4-6 stools/day over pre-treatment

2 (or higher)

Nausea

Persistent nausea resulting in decreased oral intake

2 (or higher)

Oral ulcers

Pseudomembranes or ulcerations

2 (or higher)

**Laboratory abnormalities**

Creatine phosphokinase and rhabdomyolysis

2.5 x ULN - 5 x ULN

2 (or higher)

Transaminases

ALT and/or AST > 2.5 x ULN or ALT and/or AST > 1.5 x ULN on 3 occasions over a 3-month period

2 (or higher)

Triglycerides

50 mg/dL - 300 mg/dL; 1.71 mmol/L - 3.42 mmol/L

1 (or higher)

**Musculoskeletal**

Back pain   

Moderate back pain; prescription analgesics indicated; limiting instrumental ADL

2 (or higher)

Arthralgia

Joint pain causing greater than minimal interference with usual social and functional activities

2 (or higher)

**Other**

Headache

Severe pain: pain or analgesics that severely interfere with activities of daily living

3 (or higher)
